Low levels of white blood cells, known as neutrophils, and liver-related adverse events were among the most frequently cited and noteworthy adverse events. Novartis Ag ADR stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. About a third of HR+/HER2 early breast cancer patients with stage II and more than half with stage III experience cancer recurrence.Īccording to an interim readout, the CDK4/6 inhibitor with ET cut the risk of cancer recurrence by 25.2% compared to ET alone in a broad set of patients with HR+/HER2- early breast cancer.Īs for secondary efficacy endpoints, Kisqali and ET led to 26% and 28% risk reduction in distant disease-free survival and recurrence-free survival, respectively. More than 90% of breast cancer cases are in the early stage.
NVS holds a better value than 65 of stocks at its current price. Our proprietary scoring system considers the overall health of the company by looking at the stocks price, earnings, and growth rate to determine if it represents a good value. Stock prices follow Earnings Per Share, which are trending upward. Novartis AG ( NVS) receives a strong valuation score of 65 from InvestorsObserver analysis. The stock has traded between 97.89 and 98.92 so far today. The global study was designed to evaluate Kisqali with endocrine therapy (ET) against ET alone in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer. NVS New York Stock Exchange delayed by 15 minutes CURRENCY IN USD Pharmaceuticals. Its current officers, directors and stockholders are as follows : 50 NVS / 50 NVS Stock 14 VS 31 VS 31 VS 10 VS Equity. Whats Happening With Novartis AG Stock Today Novartis AG (NVS) stock is trading at 98.67 as of 2:04 PM on Friday, Jun 2, a rise of 1.56, or 1.61 from the previous closing price of 97.11. JHVEPhoto/iStock Editorial via Getty ImagesĪnnouncing data from its pivotal study NATALEE, Novartis ( NYSE: NVS) announced Friday that its oral breast cancer therapy Kisqali as a combination regimen lowered the risk of cancer recurrence by 25% in certain patients with early breast cancer.
0 kommentar(er)
